In this real‐world study, melanoma patients with BRAF, KIT, or NRAS mutations treated with anti‐PD‐1 adjuvant monotherapy had no statistical difference of DFS compared to patients received IFN or observation. The gene discussed is RPL17; the disease is melanoma.